



**Veterinary  
Medicines  
Directorate**

**United Kingdom  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw  
Addlestone  
Surrey KT15 3LS**

**NATIONAL PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY  
MEDICINAL PRODUCT**

**Thiamapet 10 mg/ml Oral Solution for Cats**

**Date Created: March 2024**

## **MODULE 1**

### **PRODUCT SUMMARY**

Name, strength and pharmaceutical form	Thiamapet 10 mg/ml Oral Solution for Cats, Oral solution
Applicant	Equphar NV, Legeweg 157-i , 8020 Oostkamp , Belgium
Active substance	Thiamazole
ATC Vetcode	QH03BB02
Target species	Cats
Indication for use	For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long-term treatment of feline hyperthyroidism.

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)

## MODULE 3

### PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	2/1/2024

#### I. SCIENTIFIC OVERVIEW

This was determined a generic 'hybrid' application because changes to the pharmaceutical form and the excipients with regard to the reference medicinal product have been made. Bioequivalence was established with the reference product Felimazole 5 mg Coated Tablets for Cats which was first authorised in 2002.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.<sup>1</sup> The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy<sup>2</sup> of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

#### II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

##### ***II.A. Composition***

The product contains thiamazole and the excipients glycerol, sorbitol liquid (70%) and vanillin.

The container/closure system consists of an amber glass type III bottle with a polypropylene or polyethylene syringe adapter and a child-proof polypropylene screw cap. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the absence of preservative are justified.

<sup>1</sup> SPC – Summary of product Characteristics.

<sup>2</sup> Efficacy – The production of a desired or intended result.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### ***II.B. Description of the Manufacturing Method***

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of: mixing and filling.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

### ***II.C. Control of Starting Materials***

The active substance is thiamazole, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

All excipients comply with the relevant monographs.

#### ***II.C.4. Substances of Biological Origin***

Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

### ***II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process***

Not applicable.

### ***II.E. Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification. Control tests on the finished product are those for: appearance, identification, assay, density, pH, viscosity and microbiological quality.

### ***II.F. Stability***

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

### ***G. Other Information***

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging: 3 months.

This veterinary medicinal product does not require any special temperature storage conditions.

Keep the bottle tightly closed.

## **III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACOTOXICOLOGICAL)**

### ***III.A Safety Documentation***

#### ***Pharmacological Studies***

Not required due to the legal basis of the application. Bioequivalence studies were conducted to establish bioequivalence.

#### ***Toxicological Studies***

Not required.

#### ***User Safety***

A user risk assessment was provided in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:.

- People with known hypersensitivity (allergy) to thiamazole, glycerol, sorbitol or vanillin should avoid contact with the veterinary medicinal product. If allergic symptoms develop, such as a skin rash, swelling of the face, lips or eyes or difficulty in breathing, you should seek medical attention immediately and show the package leaflet or label to the doctor.
- Thiamazole may cause gastrointestinal disturbances, headache, fever, joint pain, pruritus (itching) and pancytopenia (decrease in blood cells and platelets).

- To prevent a child consuming the product, do not leave a filled syringe unattended.
- Following administration of the product any residual product remaining on the tip of the dosing syringe should be wiped clean with a tissue. The contaminated tissue should be immediately disposed of.
- The used syringe should be stored with the product in the original carton.
- In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
- This product may cause eye irritation.
- Avoid skin and eye exposure, including hand-to-eye and hand-to-mouth contact.
- Do not eat, drink or smoke while handling the product or used litter.
- Wash hands with soap and water after administration and handling of the product and cleaning the vomit of, or litter used by, treated animals. Wash any spillages or splatter from skin immediately.
- In case of accidental eye contact, rinse eyes immediately with clean running water. If irritation develops, seek medical advice.
- As thiamazole is a suspected human teratogen, women of child-bearing age must wear non-permeable single-use gloves when administering the product or handling the litter/vomit of treated cats.
- If you are pregnant, think you may be pregnant or are attempting to conceive, you should not administer the product or handle the litter/vomit of treated cats.

### ***Environmental Safety***

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

#### **Phase I:**

The product will only be used in non-food animals and as a result environmental exposure will be low. A Phase II ERA was not required.

## **IV. CLINICAL DOCUMENTATION**

### ***IV.I. Pre-Clinical Studies***

#### ***Pharmacology***

Not required due to the legal basis of the application.

#### ***Tolerance in the Target Species***

Tolerance studies were not required because of the legal basis of the application.

#### ***IV.II. Clinical Documentation***

Not required due to the legal basis of the application.

### **V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that the benefit/risk profile of the product is favourable.



## **MODULE 4**

### **POST- AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

([www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed))

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

([www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed))